Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Reuters

2024/11/21

Nov 20 (Reuters) - Kura Oncology KURA.O said on Wednesday it will collaborate with Japan's Kyowa Kirin 4151.T to develop and commercialize the blood cancer therapy ziftomenib.

Kura said it will receive an upfront payment of $330 million and up to $1.2 billion in total milestone payments as part of the deal.

(Reporting by Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi)

((Christy.Santhosh@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2485748551"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485748551\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2485748551?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 06:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485748551","market":"us","top_or_hot":-1,"title":"Kura Oncology to partner with Kyowa Kirin for blood cancer therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kura Oncology to partner with Kyowa Kirin for blood cancer therapy</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Kura Oncology <span>KURA.O</span> said on Wednesday it will collaborate with Japan's Kyowa Kirin <span>4151.T</span> to develop and commercialize the blood cancer therapy ziftomenib.</p><p>Kura said it will receive an upfront payment of $330 million and up to $1.2 billion in total milestone payments as part of the deal.</p><p> (Reporting by Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi)</p><p> ((Christy.Santhosh@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kura Oncology to partner with Kyowa Kirin for blood cancer therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKura Oncology to partner with Kyowa Kirin for blood cancer therapy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2024-11-21 06:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kura Oncology to partner with Kyowa Kirin for blood cancer therapy</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Kura Oncology <span>KURA.O</span> said on Wednesday it will collaborate with Japan's Kyowa Kirin <span>4151.T</span> to develop and commercialize the blood cancer therapy ziftomenib.</p><p>Kura said it will receive an upfront payment of $330 million and up to $1.2 billion in total milestone payments as part of the deal.</p><p> (Reporting by Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi)</p><p> ((Christy.Santhosh@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4N3MR1PC:1","article_id":"2485748551","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485748551","pubTimestamp":1732140807,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kura Oncology to partner with Kyowa Kirin for blood cancer therapyNov 20  - Kura Oncology KURA.O said on Wednesday it will collaborate with Japan's Kyowa Kirin 4151.T to develop and commercialize the blood cancer therapy ziftomenib.Kura said it will receive an upfront payment of $330 million and up to $1.2 billion in total milestone payments as part of the deal.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KURA":"Kura Oncology, Inc","BK4505":"高瓴资本持仓"},"translate_title":"Kura Oncology将与Kyowa Kirin合作开展血癌治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURA":0.9},"content_text":"Kura Oncology to partner with Kyowa Kirin for blood cancer therapyNov 20 (Reuters) - Kura Oncology KURA.O said on Wednesday it will collaborate with Japan's Kyowa Kirin 4151.T to develop and commercialize the blood cancer therapy ziftomenib.Kura said it will receive an upfront payment of $330 million and up to $1.2 billion in total milestone payments as part of the deal. (Reporting by Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi) ((Christy.Santhosh@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}